ALT5 Sigma Corp (NASDAQ: ALTS)

JanOne Inc., previously known as Appliance Recycling Centers of America, Inc., is a clinical-stage pharmaceutical company operating in the healthcare industry. The company is dedicated to developing innovative, non-opioid, and non-addictive therapies to address the significant unmet medical need of chronic pain and related conditions. JanOne's operations are based in the United States, and its primary focus is on identifying, acquiring, licensing, developing, partnering, and commercializing novel therapies for pain management.

JanOne generates revenue through the development and commercialization of its product candidates. The company's main revenue streams come from JAN101, a treatment for Peripheral Artery Disease (PAD), and JAN123, a novel formulation of low-dose naltrexone (LDN) for the treatment of chronic regional pain syndrome (CRPS). JanOne's competitive advantages include its expertise in pain biology, its experienced management team, and its focus on developing novel, non-opioid, and non-addictive therapies. The company's primary competitors are other pharmaceutical and biotechnology companies that develop or market therapies for pain management.

JanOne's customers include patients with PAD, CRPS, and other conditions that cause pain, as well as healthcare providers and payers who seek effective and safe treatments for these conditions. The company's target market is the large and growing population of patients with chronic pain, which is estimated to be over 100 million individuals in the United States and over 1.5 billion people worldwide.

JanOne's product portfolio includes JAN101, a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities and treats pain associated with PAD. The company is currently developing JAN101 through clinical trials, with the goal of transforming the standard of care for patients with PAD. Additionally, JanOne has acquired Soin Therapeutics, a company focused on the development of a novel formulation of LDN for the treatment of CRPS. CRPS is a rare pain disorder characterized by a complex set of symptoms, affecting approximately 200,000 patients annually in the US.

In terms of regulatory strategy, JanOne intends to pursue a 505(b)(2) new drug application (NDA) for JAN101, which will allow the company to rely on the FDA's prior approval of the active ingredient, sodium nitrite, as a cyanide poisoning antidote. This strategy will enable JanOne to expedite the approval process and bring JAN101 to market more efficiently.

JanOne's commercial strategy involves using third-party providers and manufacturers to support the commercialization of JAN101, if approved. The company plans to promote JAN101 to patients suffering from PAD in a cost-effective manner, leveraging digital marketing and targeted outreach to raise awareness and drive demand.

JanOne's intellectual property strategy relies on a combination of patents, trade secrets, and know-how to develop and maintain its competitive position. The company seeks to protect its proprietary information, in part, by confidentiality agreements and invention assignment agreements with its employees, consultants, scientific advisors, contractors, and commercial partners. JanOne has filed United States and foreign patent applications related to its proprietary technology, inventions, and improvements that are important to the development and implementation of its business.